Corient Private Wealth LP Invests $1.31 Million in Arrowhead Pharmaceuticals, Inc. $ARWR

Key Points

• Corient Private Wealth purchased 16,113 shares of Arrowhead Pharmaceuticals worth approximately $1.31 million during the second quarter. Institutional investors collectively own 62.61% of ARWR.
• Analysts remain generally positive, with a consensus rating of “Moderate Buy” and an average price target of $98.42, compared with the stock’s reported price of $86.34.
• Arrowhead reported quarterly revenue of $75.25 million, up 171% year over year but below expectations on adjusted earnings, posting a loss of $1.36 per share versus the $1.23-per-share consensus.

Corient Private Wealth LP purchased a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 16,113 shares of the biotechnology company's stock, valued at approximately $1,313,000.

Several other hedge funds have also added to or reduced their stakes in ARWR. Ausdal Financial Partners Inc. bought a new position in Arrowhead Pharmaceuticals during the second quarter worth $385,000. Jupiter Topco LLC bought a new stake in shares of Arrowhead Pharmaceuticals during the 2nd quarter worth about $99,623,000. Hsbc Holdings PLC bought a new stake in shares of Arrowhead Pharmaceuticals during the 2nd quarter worth about $16,765,000. Osterweis Capital Management Inc. acquired a new position in Arrowhead Pharmaceuticals in the 2nd quarter valued at about $4,101,000. Finally, Legal & General Group Plc acquired a new position in Arrowhead Pharmaceuticals in the 2nd quarter valued at about $19,335,000. Institutional investors and hedge funds own 62.61% of the company's stock.

Wall Street Analyst Weigh In

ARWR has been the topic of several research reports. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $100.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 31st. Stifel Nicolaus began coverage on Arrowhead Pharmaceuticals in a report on Tuesday, July 14th. They set a "buy" rating and a $98.00 price target for the company. HC Wainwright restated a "buy" rating and issued a $120.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday. B. Riley Financial upped their price objective on Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the company a "buy" rating in a report on Thursday, July 30th. Finally, Leerink Partners lifted their target price on Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the stock a "market perform" rating in a report on Wednesday, June 17th. Nine analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $98.42.

Insider Buying and Selling

In related news, Director Adeoye Y. Olukotun sold 2,000 shares of the firm's stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $86.96, for a total transaction of $173,920.00. Following the sale, the director owned 31,600 shares of the company's stock, valued at $2,747,936. This trade represents a 5.95% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Michael S. Perry sold 11,600 shares of the stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $87.30, for a total value of $1,012,680.00. Following the completion of the transaction, the director owned 111,459 shares of the company's stock, valued at $9,730,370.70. This represents a 9.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 3.60% of the company's stock.

Arrowhead Pharmaceuticals Trading Down 0.2%

Shares of ARWR opened at $86.34 on Friday. The company has a debt-to-equity ratio of 1.77, a quick ratio of 5.90 and a current ratio of 5.90. Arrowhead Pharmaceuticals, Inc. has a 52-week low of $27.10 and a 52-week high of $95.49. The firm has a market cap of $12.16 billion, a price-to-earnings ratio of -38.37 and a beta of 1.28. The business's fifty day moving average is $84.11 and its 200-day moving average is $74.31.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last posted its earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) EPS for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.13). The company had revenue of $75.25 million during the quarter, compared to the consensus estimate of $44.17 million. Arrowhead Pharmaceuticals had a negative return on equity of 60.06% and a negative net margin of 47.79%.The firm's revenue was up 171.0% compared to the same quarter last year. During the same period last year, the company posted ($1.26) EPS. Equities analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -3.62 EPS for the current fiscal year.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company's approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company's pipeline includes multiple candidates in various stages of development.

Want to see what other hedge funds are holding ARWR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.